Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis
dc.contributor.author | Teipel, Stefan J. | |
dc.contributor.author | Dyrba, Martin | |
dc.contributor.author | Vergallo, Andrea | |
dc.contributor.author | Lista, Simone | |
dc.contributor.author | Habert, Marie Odile | |
dc.contributor.author | Potier, Marie-Claude | |
dc.contributor.author | Lamari, Foudil | |
dc.contributor.author | Dubois, Bruno | |
dc.contributor.author | Hampel, Harald | |
dc.contributor.author | Grothe, Michel J. | |
dc.contributor.authoraffiliation | [Teipel, Stefan J.] German Ctr Neurodegenerat Dis DZNE, Rostock, Germany | |
dc.contributor.authoraffiliation | [Dyrba, Martin] German Ctr Neurodegenerat Dis DZNE, Rostock, Germany | |
dc.contributor.authoraffiliation | [Grothe, Michel J.] German Ctr Neurodegenerat Dis DZNE, Rostock, Germany | |
dc.contributor.authoraffiliation | [Teipel, Stefan J.] Univ Med Rostock, Dept Psychosomat Med, Rostock, Germany | |
dc.contributor.authoraffiliation | [Vergallo, Andrea] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, GRC 21,Alzheimer Precis Med APM, Blvd Hop, Paris, France | |
dc.contributor.authoraffiliation | [Lista, Simone] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, GRC 21,Alzheimer Precis Med APM, Blvd Hop, Paris, France | |
dc.contributor.authoraffiliation | [Hampel, Harald] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, GRC 21,Alzheimer Precis Med APM, Blvd Hop, Paris, France | |
dc.contributor.authoraffiliation | [Lista, Simone] CNRS UMR 7225, Brain & Spine Inst ICM, INSERM U 1127, Blvd Hop, Paris, France | |
dc.contributor.authoraffiliation | [Lista, Simone] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Inst Memory & Alzheimers Dis IM2A, Blvd Hop, Paris, France | |
dc.contributor.authoraffiliation | [Dubois, Bruno] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Inst Memory & Alzheimers Dis IM2A, Blvd Hop, Paris, France | |
dc.contributor.authoraffiliation | [Habert, Marie Odile] Sorbonne Univ, Lab Imagerie Biomed, CNRS, INSERM, Paris, France | |
dc.contributor.authoraffiliation | [Habert, Marie Odile] Hop La Pitie Salpetriere, AP HP, Dept Nucl Med, Paris, France | |
dc.contributor.authoraffiliation | [Habert, Marie Odile] Ctr Acquisit & Traitement Images CATI Platform, Paris, France | |
dc.contributor.authoraffiliation | [Potier, Marie-Claude] UPMC, Hop Pitie Salpetriere, ICM Inst Cerveau & Moelle Epiniere, CNRS UMR 7225,INSERM U1127, 47 Bd Hop, Paris, France | |
dc.contributor.authoraffiliation | [Lamari, Foudil] Hop La Pitie Salpetriere, UF Biochim Malad Neurometab, Serv Biochim Metab, Paris, France | |
dc.contributor.authoraffiliation | [Grothe, Michel J.] Hosp Univ Virgen del Rocio CSIC Univ Sevilla, Unidad Trastornos Movimiento, Serv Neurol & Neurofisiol Clin, Inst Biomed Sevilla, Seville, Spain | |
dc.contributor.funder | "Miguel Servet" program | |
dc.contributor.funder | Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) | |
dc.contributor.funder | Alzheimer's Disease Neuroimaging Initiative (ADNI) | |
dc.contributor.funder | National Institutes of Health | |
dc.contributor.funder | DOD ADNI (Department of Defense) | |
dc.contributor.funder | National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering | |
dc.contributor.funder | Alzheimer's Association | |
dc.contributor.funder | Alzheimer's Drug Discovery Foundation | |
dc.contributor.funder | Araclon Biotech | |
dc.contributor.funder | BioClinica, Inc. | |
dc.contributor.funder | Biogen Idec Inc. | |
dc.contributor.funder | Bristol-Myers Squibb Company | |
dc.contributor.funder | Eisai Inc. | |
dc.contributor.funder | Elan Pharmaceuticals, Inc. | |
dc.contributor.funder | Eli Lilly and Company | |
dc.contributor.funder | EuroImmun | |
dc.contributor.funder | F. Hoffmann-La Roche Ltd. | |
dc.contributor.funder | Genentech, Inc. | |
dc.contributor.funder | Fujirebio | |
dc.contributor.funder | GE Healthcare | |
dc.contributor.funder | IXICO Ltd. | |
dc.contributor.funder | Janssen Alzheimer Immunotherapy Research & Development, LLC. | |
dc.contributor.funder | Johnson & Johnson Pharmaceutical Research & Development LLC. | |
dc.contributor.funder | Medpace, Inc. | |
dc.contributor.funder | Merck Co., Inc. | |
dc.contributor.funder | Meso Scale Diagnostics, LLC. | |
dc.contributor.funder | NeuroRx Research | |
dc.contributor.funder | Neurotrack Technologies | |
dc.contributor.funder | Novartis Pharmaceuticals Corporation | |
dc.contributor.funder | Pfizer Inc. | |
dc.contributor.funder | Piramal Imaging | |
dc.contributor.funder | Servier | |
dc.contributor.funder | Synarc Inc. | |
dc.contributor.funder | Takeda Pharmaceutical Company | |
dc.contributor.funder | Canadian Institutes of Health Research | |
dc.contributor.funder | Investissement d'Avenir | |
dc.contributor.funder | Foundation Plan-Alzheimer | |
dc.contributor.funder | French Plan Alzheimer | |
dc.contributor.funder | AVID/Lilly | |
dc.date.accessioned | 2025-01-07T16:31:10Z | |
dc.date.available | 2025-01-07T16:31:10Z | |
dc.date.issued | 2021-12-22 | |
dc.description.abstract | Purpose: To test whether correcting for unspecific signal from the cerebral white matter increases the sensitivity of amyloid-PET for early stages of cerebral amyloidosis.Methods: We analyzed 18F-Florbetapir-PET and cerebrospinal fluid (CSF) A beta 42 data from 600 older individuals enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI), including people with normal cognition, mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia. We determined whether three compartmental partial volume correction (PVC-3), explicitly modeling signal spill-in from white matter, significantly improved the association of CSF A beta 42 levels with global 18F-Florbetapir-PET values compared with standard processing without PVC (non-PVC) and a widely used two-compartmental PVC method (PVC-2). In additional voxel-wise analyses, we determined the sensitivity of PVC-3 compared with non-PVC and PVC-2 for detecting early regional amyloid build-up as modeled by decreasing CSF A beta 42 levels. For replication, we included an independent sample of 43 older individuals with subjective memory complaints from the INveStIGation of AlzHeimer's PredicTors cohort (INSIGHT-preAD study).Results: In the ADNI sample, PVC-3 18F-Florbetapir-PET values normalized to whole cerebellum signal showed significantly stronger associations with CSF A beta 42 levels than non-PVC or PVC-2, particularly in the lower range of amyloid levels. These effects were replicated in the INSIGHT-preAD sample. PVC-3 18F-Florbetapir-PET data detected regional amyloid build-up already at higher (less abnormal) CSF A beta 42 levels than non-PVC or PVC-2 data.Conclusion: A PVC approach that explicitly models unspecific white matter binding improves the sensitivity of amyloid-PET for identifying the earliest stages of cerebral amyloid pathology which has implications for future primary prevention trials. | |
dc.identifier.doi | 10.3389/fnagi.2021.748198 | |
dc.identifier.issn | 1663-4365 | |
dc.identifier.pmid | 35002673 | |
dc.identifier.unpaywallURL | https://www.frontiersin.org/articles/10.3389/fnagi.2021.748198/pdf | |
dc.identifier.uri | https://hdl.handle.net/10668/27833 | |
dc.identifier.wosID | 742042800001 | |
dc.journal.title | Frontiers in aging neuroscience | |
dc.journal.titleabbreviation | Front. aging neurosci. | |
dc.language.iso | en | |
dc.organization | Instituto de Investigación Biomédica de Sevilla (IBIS) | |
dc.organization | SAS - Hospital Universitario Virgen del Rocío | |
dc.publisher | Frontiers media sa | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | amyloid PET | |
dc.subject | cerebral amyloidosis | |
dc.subject | partial volume effect | |
dc.subject | cerebrospinal fluid | |
dc.subject | Alzheimer's disease | |
dc.subject | early detection | |
dc.subject | Voxel-based analysis | |
dc.subject | Cerebrospinal-fluid | |
dc.subject | Quantitative-analysis | |
dc.subject | White-matter | |
dc.subject | Beta | |
dc.subject | Brain | |
dc.subject | Quantification | |
dc.subject | Individuals | |
dc.subject | Validation | |
dc.subject | Deposition | |
dc.title | Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 13 | |
dc.wostype | Article |